Tirzepatide produced greater average weight reduction in this trial. The result compares specific treatment regimens, not every product, patient or provider.
The comparison worth making
A comparison becomes more useful when fewer things change at once. Reading two unrelated advertisements makes that difficult: one may quote a different study, dose, population or endpoint. SURMOUNT-5 directly randomized participants between tirzepatide and semaglutide. That gives the difference between treatment groups a firmer basis than subtracting results from separate trials.
The study enrolled 751 adults with obesity without type 2 diabetes. Over 72 weeks, participants received weekly injections at their maximum tolerated trial dose: tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg. It was an open-label phase 3b trial funded by Eli Lilly.[1]
Those details belong beside the headline. “Semaglutide versus tirzepatide” is a useful shorthand, but it can conceal the actual comparison. A starter dose, a different formulation or a different patient population is not automatically represented by the result.
Common 0–25% scale. Group averages, not individual predictions. Maximum tolerated trial doses; adults without diabetes.[1]
Read the gap in percentage points
The reported mean weight reductions were 20.2% and 13.7%. Subtracting those rounded figures gives a 6.5 percentage-point gap. Dividing that gap by 13.7 gives approximately 47% greater relative reduction. Both calculations describe the same averages, but the relative number can sound much bigger when its denominator disappears.
Neither calculation means that every person taking tirzepatide lost an extra 6.5% of starting weight. An average compresses a range of individual responses. It also does not mean that someone switching medicines will gain precisely the trial difference. That would be a different question requiring a switching study.
| Statement | How to read it |
|---|---|
| 20.2% versus 13.7% | The two reported group averages at week 72. |
| 6.5 percentage points | Our subtraction of the rounded averages. |
| About 47% greater | Our relative calculation, using 13.7% as the denominator. |
For context, compare STEP 1 and SURMOUNT-1, then read how side effects and discontinuation rates change the interpretation.
What this design does not settle
Open-label means participants and investigators knew the assigned treatment. Randomization remains valuable, but it does not make every source of bias disappear. We would therefore describe the observed result with its design attached rather than presenting it as a universal ranking.
The primary question concerned body-weight change. It was not a comparison of every outcome that could matter to a particular patient: long-term cardiovascular outcomes, the experience of someone with diabetes, lifetime cost or the quality of a telehealth service. Evidence for one endpoint cannot simply be relabeled as evidence for another.
The published report describes gastrointestinal events as the most common adverse events, generally mild to moderate and concentrated during escalation. That summary does not establish that side effects are trivial or that the medicines have interchangeable safety profiles. Individual suitability still depends on clinical assessment.[1]
Funding should also be visible. Lilly funded the trial and manufactures tirzepatide. That is a reason to inspect the protocol, methods and limitations, not a reason to pretend randomization never happened or to discard the result automatically.
Turn the finding into a better shortlist
Separate the medicine decision from the service decision. First discuss whether either treatment is suitable for your history and goals. Then identify what product the service would actually prescribe and dispense. A provider selling a product with a familiar ingredient name has not thereby demonstrated that its formulation reproduces this trial.
Next compare the support and the bill. Ask who manages dose changes, how follow-up works, and what happens financially if treatment changes. A larger published mean reduction cannot answer whether an enrollment fee is refundable or whether the quoted price includes medicine. Those are service terms, and they need separate evidence.
Our practical reading is to give this trial substantial weight for its defined comparison while refusing to let it do unrelated jobs. A credible provider comparison should not turn the larger number into a promised personal outcome, a reason to skip evaluation, or a blanket endorsement of every offer featuring that ingredient.
For the next step, compare provider models and use the cost worksheet to keep medication and care charges separate. Our STEP 1 versus SURMOUNT-1 analysis explains why older cross-trial charts need more caution.
For the brand-level decision, read Wegovy versus Mounjaro. If you already take semaglutide, our switching analysis explains why the trial gap is not a conversion rule.